文献速递乳腺癌放疗放疗物理与技术

三分类腔内加速部分乳腺近距离放疗:一种新方案的早期提供者与患者报告结局

Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-12-21

本研究报道了73例≥50岁、肿瘤≤2.5 cm且淋巴结阴性的乳腺癌患者接受3次腔内导管部分乳腺近距离放疗(ICBB)的早期不良事件与患者报告结局。处方剂量为21 Gy分3次每日一次,中位随访14个月,≥2级不良事件仅2例(3%)乳腺感染,12个月时91%患者总体生活质量评分≥8分、95%患者报告美容效果良好或极好。作者认为该方案早期不良事件率低,与NSABP B-39中更长时间ICBB方案相比具有优势,但需进一步研究。

要点

  • 73例患者接受21 Gy分3次ICBB,中位随访14个月,仅2例(3%)出现需口服抗生素的乳腺感染。
  • 3个月1级血清肿发生率为20%,12个月降至8%,均无需干预。
  • 12个月时91%患者总体生活质量评分≥8/10,95%患者报告美容效果良好或极好。

核心结论

  • 3次ICBB与低早期提供者和患者报告不良事件率相关,与NSABP B-39中每日两次(3.4 Gy×10)分割等更长时间ICBB方案的早期结局相比具有优势,需进一步研究。

研究设计与样本

  • 单臂研究,纳入≥50岁、肿瘤≤2.5 cm、淋巴结阴性的浸润性或原位乳腺癌患者73例,接受保乳手术并放置近距离放疗施源器。
  • ICBB于术后第二个工作日开始,处方剂量21 Gy分3次每日一次。
  • 采用常见不良事件评价标准第4.0版、10分线性模拟量表、常见不良事件评价标准患者报告版及哈佛乳腺美容量表进行评估。

主要发现

  • 73例中浸润性癌79%、原位癌21%,手术至放疗完成的中位时间为6天。
  • 中位随访14个月,2例(3%)出现乳腺感染并经口服抗生素治愈,无其他≥2级治疗相关不良事件。
  • 3个月1级血清肿发生率为20%,12个月降至8%,无事件需干预。
  • 12个月时91%患者报告总体生活质量评分≥8/10,95%患者报告美容效果良好或极好。
  • 末次随访时所有患者存活且无复发。

关键数值与推荐

  • 处方剂量为21 Gy分3次每日一次。
  • 3个月1级血清肿发生率为20%,12个月为8%。
  • 12个月时91%患者总体生活质量评分≥8/10,95%患者美容效果良好或极好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者结论指出需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report early adverse events and patient-reported outcomes (PROs) of 3-fraction intracavitary catheter-based partial breast brachytherapy (ICBB). MATERIALS AND METHODS: Eligible women ≥50 years of age with ≤2.5-cm, lymph node-negative invasive or in situ breast cancer underwent breast-conserving surgery and placement of a brachytherapy applicator. ICBB was initiated on the second weekday after surgery and prescribed to 21 Gy in 3 once-daily fractions. Common Terminology Criteria for Adverse Events, version 4.0; 10-point linear analog scale assessment; the PRO version of the Common Terminology Criteria for Adverse Events; and the Harvard Breast Cosmesis Scale were used for provider and patient-reported assessments. RESULTS: Seventy-three women were treated for invasive (79%) or in situ (21%) breast cancer. The median time to completion of surgery and radiation therapy was 6 days. After 14-months median follow-up, 2 patients (3%) had developed breast infections that resolved with oral antibiotics. There was no other treatment-associated adverse event grade ≥2. The grade 1 seroma rate at 3 months was 20%, which dropped to 8% at 12 months; no events required intervention. At 12 months, 91% of patients reported an overall quality of life score as ≥8 of 10, and patient-reported cosmesis was good or excellent in 95%. All patients are alive without relapse at the last follow-up. CONCLUSIONS: Three-fraction ICBB is associated with low rates of early provider and patient- reported adverse events and compares favorably with early outcomes of more protracted ICBB regimens, including twice-daily (3.4 Gy × 10) fractionation studied in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-39. Further investigation is warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jethwa KR, Park SS, Gonuguntla K, et al. Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen. Int J Radiat Oncol Biol Phys. 2018. PMID: 30583041. doi:10.1016/j.ijrobp.2018.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。